Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi ® (STO:SOBI) today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli ® (pegcetacoplan) ...

Apellis (APLS) and Sobi announced the European Medicines Agency has validated an indication extension application for Aspaveli for the ...

which along with PNH and IgAN include atypical haemolytic uraemic syndrome (aHUS), C3 glomerulopathy (C3G), and idiopathic membranous nephropathy (IMN). IgAN is a key focus for Novartis ...

An FDA advisory committee panel is scheduled to discuss the merits of Novartis’ oral factor B inhibitor Fabhalta in the rare kidney disease C3 glomerulopathy (C3G). The Cardiovascular and Renal ...

which along with PNH and IgAN include atypical haemolytic uraemic syndrome (aHUS), C3 glomerulopathy (C3G), and idiopathic membranous nephropathy (IMN). It still has a long way to go to reach that ...

HC Wainwright reiterated their buy rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) in a research report released on Thursday morning,Benzinga reports. HC Wainwright currently ...

Feb. 17, 2025 — In a surprising discovery, scientists have found that the heart possesses 'sweet taste' receptors, similar to those on our tongues, and that stimulating these receptors with ...

June 10, 2024 — Scientists have grown 'mini-guts' in the lab to help understand Crohn's disease, showing that 'switches' that modify DNA in gut cells play an ... Major Cause of Inflammatory ...

Kidney stones are pebble-sized deposits that form when there’s too much salt and minerals in your urine. Learn whether men or women are more at risk, what passing one feels like, and how big ...